Skip to main
HURA
HURA logo

HURA Stock Forecast & Price Target

HURA Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TuHURA Biosciences Inc. is advancing its personalized cancer vaccine candidate, IFx-2.0, into a critical Phase 3 registration trial, demonstrating significant progress in its development pipeline. The company’s strategic focus on overcoming resistance to established cancer therapies, particularly through the combination of IFx-2.0 and Keytruda, positions it favorably within the immuno-oncology market. With the Phase 3 trial's initiation, TuHURA is poised to capitalize on increasing market demand for innovative cancer treatments, bolstering its potential for revenue generation and long-term growth.

Bears say

The financial outlook for TuHURA Biosciences appears concerning, as the company reported a net loss of $0.15 per share for 1Q25, which aligns closely with prior estimates but indicates sustained financial losses. Furthermore, the company faces significant risks including potential negative clinical results for its lead candidate, IFx-2.0, delays in progressing its pipeline, and challenges in securing timely regulatory approvals. Coupled with competitive pressures in the immuno-oncology space and the risk of long-term dilution, these factors contribute to an overall negative outlook for the company's stock performance.

HURA has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TuHURA Biosciences Inc (HURA) Forecast

Analysts have given HURA a Strong Buy based on their latest research and market trends.

According to 2 analysts, HURA has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TuHURA Biosciences Inc (HURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.